Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Exelixis, Inc announces positive top line results for phase 3 pivotal trial of cobimetinib in combination with vemurafenib


Monday, 14 Jul 2014 01:00am EDT 

Exelixis, Inc:Announces positive top line results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis.Says it is in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAF(V600)mutation.Exelixis' collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its primary endpoint, delivering a statistically increase in progression-free survival (PFS) for the combination of cobimetinib plus vemurafenib as compared to vemurafenib alone.Adverse events were consistent with those observed in a previous study of the combination. 

Company Quote

1.62
0.045 +2.86%
1:40pm EDT